Search Results

There are 9607 results for: content related to: Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

  1. Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 878–894, Dr Jack J. Chen and Dr David M. Swope

    Version of Record online : 19 MAR 2013, DOI: 10.1177/0091270005277935

  2. Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

    The Journal of Clinical Pharmacology

    Volume 50, Issue 12, December 2010, Pages: 1420–1428, Tamar Goren, Liat Adar, Nissim Sasson and Yoni M. Weiss

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010369674

  3. You have free access to this content
    Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline

    British Journal of Pharmacology

    Volume 143, Issue 3, October 2004, Pages: 371–378, Zaid A Abassi, Ofer Binah and Moussa B H Youdim

    Version of Record online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705962

  4. You have free access to this content
    Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

    Journal of Neurochemistry

    Volume 105, Issue 5, June 2008, Pages: 1970–1978, Wen Zhu, Wenjie Xie, Tianhong Pan, Joseph Jankovic, Jun Li, Moussa B. H. Youdim and Weidong Le

    Version of Record online : 8 MAR 2008, DOI: 10.1111/j.1471-4159.2008.05330.x

  5. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  6. You have free access to this content
    Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat

    British Journal of Pharmacology

    Volume 149, Issue 6, November 2006, Pages: 647–656, J P M Finberg, A Gross, O Bar-Am, R Friedman, Y Loboda and M B H Youdim

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706908

  7. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  8. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease

    International Journal of Clinical Practice

    Volume 60, Issue 2, February 2006, Pages: 215–221, F. Stocchi

    Version of Record online : 1 FEB 2006, DOI: 10.1111/j.1742-1241.2006.00806.x

  9. The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

    The Journal of Clinical Pharmacology

    Volume 52, Issue 5, May 2012, Pages: 620–628, Dr Jack J. Chen and Dr Jayne R. Wilkinson

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011406279

  10. You have free access to this content
    Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

    British Journal of Pharmacology

    Volume 132, Issue 2, January 2001, Pages: 500–506, Moussa B H Youdim, Aviva Gross and John P M Finberg

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0703826

  11. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

    Movement Disorders

    Volume 19, Issue 8, August 2004, Pages: 916–923, Matthew B. Stern, Kenneth L. Marek, Joseph Friedman, Robert A. Hauser, Peter A. LeWitt, Daniel Tarsy and C. Warren Olanow

    Version of Record online : 27 APR 2004, DOI: 10.1002/mds.20145

  12. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease

    European Journal of Neurology

    Volume 19, Issue 2, February 2012, Pages: 258–264, E. Tolosa and M. B. Stern

    Version of Record online : 5 AUG 2011, DOI: 10.1111/j.1468-1331.2011.03484.x

  13. Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 12, December 2014, Pages: 1250–1258, Michel Panisset, Jack J. Chen, Sean H. Rhyee, Jill Conner, Julie Mathena and the STACCATO study investigators

    Version of Record online : 14 OCT 2014, DOI: 10.1002/phar.1500

  14. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications

    Intervention Review

    The Cochrane Library

    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley and Alex Furmston

    Published Online : 7 JUL 2010, DOI: 10.1002/14651858.CD007166.pub2

  15. Efficacy and tolerability of rasagiline in daily clinical use – a post-marketing observational study in patients with Parkinson’s disease

    European Journal of Neurology

    Volume 17, Issue 9, September 2010, Pages: 1164–1171, H. Reichmann and W. H. Jost

    Version of Record online : 17 MAR 2010, DOI: 10.1111/j.1468-1331.2010.02986.x

  16. Parkinson's Disease

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 13 OCT 2006, DOI: 10.1002/9780470041000.cedt084

  17. The Anti-Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo

    Annals of the New York Academy of Sciences

    Volume 939, Issue 1, June 2001, Pages: 450–458, MOUSSA B.H. YOUDIM, A. WADIA, W. TATTON and MARTA WEINSTOCK

    Version of Record online : 25 JAN 2006, DOI: 10.1111/j.1749-6632.2001.tb03656.x

  18. You have full text access to this OnlineOpen article
    A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients

    European Journal of Neurology

    Volume 22, Issue 8, August 2015, Pages: 1184–1191, P. Barone, G. Santangelo, L. Morgante, M. Onofrj, G. Meco, G. Abbruzzese, U. Bonuccelli, G. Cossu, G. Pezzoli, P. Stanzione, L. Lopiano, A. Antonini and M. Tinazzi

    Version of Record online : 12 MAY 2015, DOI: 10.1111/ene.12724

  19. Improving l-dopa therapy: The development of enzyme inhibitors

    Movement Disorders

    Volume 30, Issue 1, January 2015, Pages: 103–113, Oscar S. Gershanik

    Version of Record online : 21 OCT 2014, DOI: 10.1002/mds.26050

  20. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

    Movement Disorders

    Volume 24, Issue 4, 15 March 2009, Pages: 564–573, Robert A. Hauser, Mark F. Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek and Cheryl J. Fitzer-Attas

    Version of Record online : 11 DEC 2008, DOI: 10.1002/mds.22402